阿伯西普联合以氟尿嘧啶为基础的化疗治疗晚期大肠癌的研究-培训课件.pptVIP

读书报告 汇报人：罗娜 1 BACKGROUND 2 PATIENTS?AND METHODS 3 RESULTS 4 CONCLUSIONS Background Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and response rate. 1 01 typically regimen 02 FOLFOX+bevacizumab 03 FOLFIRI+aflibercept 04 Aflibercept Background typically regimen Treatment of metastatic colorectal cancer (mCRC) typically involves a fluoropyrimidine-based hemotherapy regimen, combining infusional fluorouracil (5-FU) and leucovorin with oxaliplatin (FOLFOX regimen) or rinotecan (FOLFIRI regimen). [1] Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23–30. [2] Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343(13):905–14. [3] Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229–37. FOLFOX+bevacizumab In the E3200 study, it was shown that the addition of bevacizumab to FOLFOX improves survival duration for patients with previously treated mCRC who had not received first-line treatment with oxaliplatin or bev-acizumab. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539–44. FOLFIRI+aflibercept VEGF Trap (aflibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen (VELOUR) was the first randomised, placebo-controlled, phase III trial to show